This company seems to have been delisted
Reason: Merged with Sun Pharma
Last recorded trade on: August 23, 2024
Source: https://www.prnewswire.com/news-releases/sun-pharma-completes-taro-merger-302180230.html
Reason: Merged with Sun Pharma
Last recorded trade on: August 23, 2024
Source: https://www.prnewswire.com/news-releases/sun-pharma-completes-taro-merger-302180230.html
Taro Pharmaceutical
TARO
A$65.86
Share price
0.00%
Change (1 day)
8.63%
Change (1 year)
Categories
Taro Pharmaceutical (TARO) - Total assets
Total assets on the balance sheet as of December 2023 : A$3.31 Billion
According to Taro Pharmaceutical's latest financial reports the company's total assets are A$3.31 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Taro Pharmaceutical - Total assets on balance sheet (from 2001 to 2023)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2023-03-31 | A$3.18 B | 9.76% |
| 2022-03-31 | A$2.90 B | -8.34% |
| 2021-03-31 | A$3.16 B | -16.92% |
| 2020-03-31 | A$3.81 B | 27.1% |
| 2019-03-31 | A$3.00 B | -5.22% |
| 2018-03-31 | A$3.16 B | 5.75% |
| 2017-03-31 | A$2.99 B | 4.97% |
| 2016-03-31 | A$2.85 B | 24.99% |
| 2015-03-31 | A$2.28 B | 64.71% |
| 2014-03-31 | A$1.38 B | 30.38% |
| 2013-03-31 | A$1.06 B | |
| 2011-12-31 | A$0.77 B | 41.69% |
| 2010-12-31 | A$0.54 B | -14.55% |
| 2009-12-31 | A$0.64 B | -4.4% |
| 2008-12-31 | A$0.67 B | 21.29% |
| 2007-12-31 | A$0.55 B | 2.62% |
| 2006-12-31 | A$0.53 B | -28.09% |
| 2005-12-31 | A$0.74 B | -16.8% |
| 2004-12-31 | A$0.90 B | 8.57% |
| 2003-12-31 | A$0.82 B | 23.03% |
| 2002-12-31 | A$0.67 B | 11.8% |
| 2001-12-31 | A$0.60 B |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | A$318.84 B | 9,516.77% | 🇺🇸 USA |
 Merck MRK | A$176.44 B | 5,221.89% | 🇺🇸 USA |
 Johnson & Johnson JNJ | A$296.83 B | 8,853.07% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | A$58.87 B | 1,675.86% | 🇮🇱 Israel |
 GlaxoSmithKline GSK | A$120.21 B | 3,525.97% | 🇬🇧 UK |
 Novartis NVS | A$153.17 B | 4,520.10% | 🇨🇭 Switzerland |